Metastatic Bone Tumor Clinical Trial
Official title:
The International Skeletal Metastasis Registry
This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)
The registry is designed to update a suite of clinical decision-support tools designed for use when treating patients with metastatic bone disease. The models estimate the likelihood of survival at 1, 3, 6, 12, 18, and 24 months post surgery, which in turn, may be used for surgical decision-making. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05115331 -
Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease
|
Phase 3 | |
| Recruiting |
NCT04634227 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
|
Early Phase 1 | |
| Completed |
NCT04660591 -
Length of the Femoral Stem in Arthroplasty Done for Patients With Proximal Femoral Metastatic Lesion
|
N/A | |
| Completed |
NCT05110430 -
Automated Detection of Metastatic Bone Disease on Bone Scintigraphy Scans
|
||
| Not yet recruiting |
NCT04364724 -
CTFEA Myeloma Study
|
||
| Recruiting |
NCT05427825 -
ERAS Anesthetic Care for Metastatic Spine Cancer Resection
|
N/A | |
| Terminated |
NCT03468075 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults
|
Phase 2 | |
| Active, not recruiting |
NCT03963531 -
Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
|